In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial. The post Breaking News: Cybin to Acquire...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
The company expects its current cash to fund it into 2026. The post GH Research Progresses Deeper Into Toad Venom Research appeared first on Green Market...
Atai Life Sciences Q2 financial results were released recently, alongside an update on the company’s pipeline progression. So, we figured it would be...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 The post Cybin...
Cybin reports first quarter financial results and business highlights, including updates on key trials. The post Cybin Reports Q1 Financial Results and...
-Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...